Kyverna Therapeutics, Inc. (KYTX) bonds
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.48−0.22 (-4.68%)
Close on Nov 18, 2026Market cap $277.06MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$24.96M
Long-term debt
Net debt
-$6.86M
After $31.82M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
-347.3×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Kyverna Therapeutics's 10-K for the period ended Oct 31, 2025
Kyverna Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Initial Tranche | $40.00M |
| Tranche Four | $50.00M |
| Tranche Two and Three | $60.00M |
See a number that looks wrong?